

Clinical trials of extended tinzaparin

TrialResults-center www.trialresultscenter.org

1 venous thrombosis

Trial	Treatments	Patients	Trials design and methods
extended tinzaparin vs standard treatment			
Hull , 2006 n=NA follow-up: 3 months	Tinzaparin 175 antiXa/kg SQ daily for 12 weeks versus UFH for 5 days followed by vitamin K antagonist (target INR 2-3) for 12 weeks	patients with cancer (solid or hematological) with proximal DVT with or without PE and with a minimum life expectancy of 3 months	Parallel groups outcome assessment blinded

More details and results :

- antithrombotics for venous thrombosis in patients with cancer at <http://www.trialresultscenter.org/go-Q103>

References

Hull, 2006:

Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062-72 [[17145251](#)]

Entry terms: tinzaparin, tinzaparin, tinzaparin sodium, Innohep, Leo brand of tinzaparin sodium, Bristol-Myers Squibb brand of tinzaparin sodium,